8-K Announcements
6Material company update
Apr 20, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 13, 2026·SEC
Evommune, Inc.(EVMN)Earnings, Financials & Key Ratios
EVMN•NYSE
Price updated Jun 11, 2026
- Revenue$13M+85.7%
- EBITDA-$80M-15.9%
- Net Income-$69M-3.1%
- EPS (Diluted)-2.18+4.0%
- Gross Margin89.32%+9.4%
- EBITDA Margin-612.94%+37.6%
- Operating Margin-623.62%+37.6%
- Net Margin-529.77%+44.5%
- ROE-224.59%
- ROIC-61.92%+54.8%
- Debt/Equity0.01
- Interest Coverage-11581.57-489.7%
EVMN Key Insights
Evommune, Inc. (EVMN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when EVMN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
EVMN Price & Volume
Evommune, Inc. (EVMN) stock price & volume — 10-year historical chart
Loading chart...
EVMN Growth Metrics
Evommune, Inc. (EVMN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years-75.72%
5 Years-75.72%
3 Years-75.72%
Last Year-63.56%
EVMN Recent Earnings
Evommune, Inc. (EVMN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/4 qtrs (50%)●Beat Revenue 1/4 qtrs (100%)
Q2 2026Latest
May 7, 2026EPS
$0.64
Est $0.83
+22.9%
Revenue
—
Est $722,167
Q2 2026
Mar 5, 2026EPS
$1.43
Est $0.82
-74.4%
Revenue
—
Q1 2026
Feb 25, 2026EPS
$0.78
Est $0.82
+4.5%
Revenue
—
Q4 2025
Dec 11, 2025EPS
$8.07
Est $6.08
-32.7%
Revenue
$10M
Est $3M
+200.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.64vs $0.83+22.9% | —vs $722,167 |
| Q2 2026 | Mar 5, 2026 | $1.43vs $0.82-74.4% | — |
| Q1 2026 | Feb 25, 2026 | $0.78vs $0.82+4.5% | — |
| Q4 2025 | Dec 11, 2025 | $8.07vs $6.08-32.7% | $10Mvs $3M+200.0% |
Based on last 4 quarters of dataView full earnings history →
EVMN Peer Comparison
Evommune, Inc. (EVMN) competitors in industry — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 ARDX | 1.42B | 5.79 | -22.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 CLDX | 1.99B | 29.96 | -7.68 | -78.63% | -345.96% | -50.72% | 0.00 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 RAPT | 295.54M | 58.01 | -2.28 | -61.81% | 0.02 | |||
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 REGN | 63.53B | 611.48 | 14.74 | 0.99% | 29.65% | 14.32% | 0.09 | |
 ABBV | 397.56B | 224.77 | 94.84 | 8.57% | 6.91% | 62.15% |
Compare EVMN vs Peers
Evommune, Inc. (EVMN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EVMN Income Statement
Evommune, Inc. (EVMN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|
Sales/Revenue | 5M | 7M | 13M |
Revenue Growth % | - | 40% | 85.71% |
Cost of Goods Sold | 1M | 1.29M | 1.39M |
COGS % of Revenue | 20% | 18.39% | 10.68% |
Gross Profit | 4M▲ 0% | 5.71M▲ 42.8% | 11.61M▲ 103.2% |
Gross Margin % | 80% | 81.61% | 89.32% |
Gross Profit Growth % | - | 42.83% | 103.24% |
Operating Expenses | 41.85M | 75.73M | 92.68M |
OpEx % of Revenue | 837% | 1081.8% | 712.94% |
Selling, General & Admin | 9.85M | 11.48M | 18.64M |
SG&A % of Revenue | 197.06% | 164.03% | 143.38% |
Research & Development | 32M | 64.24M | 74.04M |
R&D % of Revenue | 639.94% | 917.77% | 569.55% |
Other Operating Expenses | 0 | 0 | 0 |
Operating Income | -37.85M▲ 0% | -70.01M▼ 85.0% | -81.07M▼ 15.8% |
Operating Margin % | -757% | -1000.19% | -623.62% |
Operating Income Growth % | - | -84.97% | -15.79% |
EBITDA | -36.85M | -68.73M | -79.68M |
EBITDA Margin % | -737% | -981.8% | -612.94% |
EBITDA Growth % | - | -86.5% | -15.94% |
D&A (Non-Cash Add-back) | 1M | 1.29M | 1.39M |
EBIT | -33.99M | -66.77M | -81.07M |
Net Interest Income | 3.8M | 3.21M | 3.32M |
Interest Income | 3.86M | 3.24M | 3.32M |
Interest Expense | 58K | 34K | 7K |
Other Income/Expense | 3.8M | 3.2M | 12.2M |
Pretax Income | -34.05M▲ 0% | -66.81M▼ 96.2% | -68.87M▼ 3.1% |
Pretax Margin % | -681.06% | -954.4% | -529.77% |
Income Tax | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% |
Net Income | -34.05M▲ 0% | -66.81M▼ 96.2% | -68.87M▼ 3.1% |
Net Margin % | -681.06% | -954.4% | -529.77% |
Net Income Growth % | - | -96.19% | -3.09% |
Net Income (Continuing) | -34.05M | -66.81M | -68.87M |
Discontinued Operations | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 |
EPS (Diluted) | -1.13▲ 0% | -2.27▼ 100.9% | -2.18▲ 4.0% |
EPS Growth % | - | -100.89% | 3.96% |
EPS (Basic) | -1.13 | -2.27 | -2.18 |
Diluted Shares Outstanding | 30.08M | 30.08M | 31.52M |
Basic Shares Outstanding | 30.08M | 30.08M | 31.52M |
Dividend Payout Ratio | - | - | - |
EVMN Balance Sheet
Evommune, Inc. (EVMN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|
Total Current Assets | 80.03M | 73.99M | 153.48M |
Cash & Short-Term Investments | 79.08M | 72.04M | 149.2M |
Cash Only | 29.02M | 16.25M | 44.06M |
Short-Term Investments | 50.06M | 55.78M | 105.14M |
Accounts Receivable | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - |
Inventory | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - |
Other Current Assets | 948K | 1.95M | 4.28M |
Total Non-Current Assets | 2.22M | 2.07M | 71.47M |
Property, Plant & Equipment | 1.97M | 1.8M | 2.46M |
Fixed Asset Turnover | 2.54x | 3.89x | 5.28x |
Goodwill | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 |
Long-Term Investments | 208K | 208K | 68.9M |
Other Non-Current Assets | 44K | 61K | 101K |
Total Assets | 82.25M▲ 0% | 76.06M▼ 7.5% | 224.95M▲ 195.8% |
Asset Turnover | 0.06x | 0.09x | 0.06x |
Asset Growth % | - | -7.53% | 195.77% |
Total Current Liabilities | 6.86M | 27.98M | 17.91M |
Accounts Payable | 1.76M | 8.26M | 7.76M |
Days Payables Outstanding | 641.67 | 2.34K | 2.04K |
Short-Term Debt | 769K | 1.02M | 589K |
Deferred Revenue (Current) | 0 | 3M | 0 |
Other Current Liabilities | 1.89M | 12.06M | 4.63M |
Current Ratio | 11.67x | 2.64x | 8.57x |
Quick Ratio | 11.67x | 2.64x | 8.57x |
Cash Conversion Cycle | - | - | - |
Total Non-Current Liabilities | 153.11M | 192.31M | 1.47M |
Long-Term Debt | 149.37M | 191.78M | 0 |
Capital Lease Obligations | 487K | 519K | 1.47M |
Deferred Tax Liabilities | 0 | 0 | 0 |
Other Non-Current Liabilities | 245K | 16K | 0 |
Total Liabilities | 159.96M | 220.29M | 19.38M |
Total Debt | 150.63M | 193.31M | 2.06M |
Net Debt | 121.61M | 177.06M | -42M |
Debt / Equity | - | - | 0.01x |
Debt / EBITDA | - | - | - |
Net Debt / EBITDA | - | - | - |
Interest Coverage | -586.12x | -1963.94x | -11581.57x |
Total Equity | -77.71M▲ 0% | -144.24M▼ 85.6% | 205.57M▲ 242.5% |
Equity Growth % | - | -85.6% | 242.52% |
Book Value per Share | -2.58 | -4.80 | 6.52 |
Total Shareholders' Equity | -77.71M | -144.24M | 205.57M |
Common Stock | 1K | 1K | 3K |
Retained Earnings | -83.91M | -152.22M | -221.09M |
Treasury Stock | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 |
EVMN Cash Flow Statement
Evommune, Inc. (EVMN) cash flow — operating, investing & free cash flow history
| Metric | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|
Cash from Operations | -29.97M | -58.2M | -76.44M |
Operating CF Margin % | -599.4% | -831.36% | -588.01% |
Operating CF Growth % | - | -94.18% | -31.35% |
Net Income | -34.05M | -66.81M | -68.87M |
Depreciation & Amortization | 1M | 1.29M | 1.39M |
Stock-Based Compensation | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 |
Other Non-Cash Items | -261K | -98K | -4.84M |
Working Capital Changes | 3.34M | 7.42M | -4.12M |
Change in Receivables | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 |
Change in Payables | 125K | 6.51M | -837K |
Cash from Investing | -48.43M | -3.99M | -115.31M |
Capital Expenditures | -118K | -88K | -235K |
CapEx % of Revenue | 2.36% | 1.26% | 1.81% |
Acquisitions | 0 | 0 | 0 |
Investments | - | - | - |
Other Investing | 0 | 0 | 0 |
Cash from Financing | 63.75M | 49.42M | 220.76M |
Debt Issued (Net) | 0 | 0 | -373K |
Equity Issued (Net) | 63.98M | 49.84M | 222.36M |
Dividends Paid | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 |
Other Financing | -230K | -423K | -1.22M |
Net Change in Cash | 29.02M▲ 0% | -12.77M▼ 144.0% | 27.81M▲ 317.8% |
Free Cash Flow | -30.09M▲ 0% | -58.28M▼ 93.7% | -76.68M▼ 31.6% |
FCF Margin % | -601.76% | -832.61% | -589.82% |
FCF Growth % | - | -93.71% | -31.56% |
FCF per Share | -1.00 | -1.94 | -2.43 |
FCF Conversion (FCF/Net Income) | 0.88x | 0.87x | 1.11x |
Interest Paid | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 |
EVMN Key Ratios
Evommune, Inc. (EVMN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Return on Equity (ROE) | - | - | -224.59% |
| Return on Invested Capital (ROIC) | - | -136.9% | -61.92% |
| Gross Margin | 80% | 81.61% | 89.32% |
| Net Margin | -681.06% | -954.4% | -529.77% |
| Debt / Equity | - | - | 0.01x |
| Interest Coverage | -586.12x | -1963.94x | -11581.57x |
| FCF Conversion | 0.88x | 0.87x | 1.11x |
| Revenue Growth | - | 40% | 85.71% |
Related:EVMN Dividend History·EVMN Revenue History·EVMN Price History·EVMN P/E History·EVMN Financial Ratios·EVMN Institutional Holders
EVMN SEC Filings & Documents
Evommune, Inc. (EVMN) SEC filings — annual & quarterly reports (10-K, 10-Q)
EVMN Frequently Asked Questions
Evommune, Inc. (EVMN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Evommune, Inc. (EVMN) reported $13.0M in revenue for fiscal year 2025. This represents a 160% increase from $5.0M in 2023.
Evommune, Inc. (EVMN) grew revenue by 85.7% over the past year. This is strong growth.
Evommune, Inc. (EVMN) reported a net loss of $68.9M for fiscal year 2025.
Dividend & Returns
Evommune, Inc. (EVMN) has a return on equity (ROE) of -224.6%. Negative ROE indicates the company is unprofitable.
Evommune, Inc. (EVMN) had negative free cash flow of $76.7M in fiscal year 2025, likely due to heavy capital investments.